Concepedia

William W. Feng

WW

Statistics

Publications

17

Citations

1K

H-Index

15

Active since

2005

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

Dartmouth College

Broad Institute

Kent State University

William W. Feng is an author at Dana-Farber Cancer Institute specializing in molecular oncology, oncology, and medicine.

Publications per year

2005–2025

17

Publications

17

CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies

William W. Feng, Owen M. Wilkins, Scott Bang et al. · Cell Reports · 2019 · 214 citations · Full text

Medicine, Biochemistry, Oncology +17

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer

Ciric To, Tyler S. Beyett, Jaebong Jang et al. · Nature Cancer · 2022 · 161 citations · Full text

Medicine, Oncology, Pharmacology +15

Transferrin receptor targeting chimeras for membrane protein degradation

Dingpeng Zhang, Jhoely Duque-Jimenez, Francesco Facchinetti et al. · Nature · 2024 · 147 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +14

The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272

Yuko Minami, Takeshi Shimamura, Kinjal Shah et al. · Oncogene · 2007 · 110 citations

Medicine, Molecular Biology, Oncology +13

Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer

Fernando J. de Miguel, Claudia Gentile, William W. Feng et al. · Cancer Cell · 2023 · 108 citations · Full text

Medicine, Molecular Biology, Oncology +17

1–5 of 17